Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olea europaea + phleum pratense is a combination of two allergen extracts derived from *Olea europaea* (olive pollen) and *Phleum pratense* (timothy grass pollen). These allergens are among the most common causes of respiratory allergic diseases, such as allergic rhinitis and allergic asthma, particularly in regions where both olive trees and grasses are prevalent. Combination preparations of these pollen extracts may be used in allergen immunotherapy, aiming to modulate the immune response and reduce symptoms in individuals sensitized to both pollens. The mechanism is believed to involve immune tolerance induction, most likely mediated by regulatory cytokines such as IL-10 and IL-35, reducing IgE-mediated hypersensitivity and inflammatory responses[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olea europaea + phleum pratense.